Supplementary MaterialsS1 Table: Primer pairs used in this study for gene expression analysis by RT-qPCR

Supplementary MaterialsS1 Table: Primer pairs used in this study for gene expression analysis by RT-qPCR. for siRNA-CN and n = 2 for siRNA-1). Expression of SDHA gene is used as reference. D. Western blot analysis of pRB, total CASP7, cleaved CASP7, BCL2, BAX, total CHEK1, pCHEK1, pH2AX proteins from siRNA-1 and siRNA-CN treated groups (n = 2 per group). E. Densitometry analysis and statistical comparisons. Students t-test was applied. (*: p 0.05, **: p 0.01, #: p 0.001).(TIF) pone.0208982.s006.tif (1.7M) GUID:?9749433E-A1AA-490F-A1D7-084C9C64DAD8 S2 Fig: Validations for RNAi molecules in MCF7, BT-20 and MDA-MB-231 cells. A. CHRNA5 levels in siRNA-1 treated BT20 and MDA-MB-231 cell line (n = 2 per group). B. Relative cell viability of MCF7 cells upon siRNA-1-3 exposure (n = 3 per group). C-D. Relative cell viability of BT20 (C) MDA-MB-231 upon siRNA-1 exposure (D) (n = 3 per group). (*: p 0.05, **: p 0.01, ***: p 0.001, ****: MAK-683 p 0.0001).(TIF) pone.0208982.s007.tif Mouse monoclonal to CD10.COCL reacts with CD10, 100 kDa common acute lymphoblastic leukemia antigen (CALLA), which is expressed on lymphoid precursors, germinal center B cells, and peripheral blood granulocytes. CD10 is a regulator of B cell growth and proliferation. CD10 is used in conjunction with other reagents in the phenotyping of leukemia (589K) GUID:?D0C94CC0-1F42-4AEF-8CD9-4AA16017EB92 S3 Fig: Validations for apoptosis, cyclin and DDR related expression in breast cancer cell lines. A-B. One-Way ANOVA of densitometry measurements of cleaved CASP7/total CASP7 ratio (A) and pH2AX (B) in MCF7 cells. siRNA-CN (10nM) and siRNA-CN (50nM) were used as control groups for siRNA-1, and siRNA-2-3, respectively. (n = 2 per group for siRNA-CN (10nM) and siRNA-1; n = 3 per group for siRNA-CN (50nM) and siRNA-2 and -3). C. FAS and BID protein levels upon siRNA-1 treatment for 72h (left) and 120h (right) in MCF7 cells and densitometry analysis with students t-test. D. RT-qPCR analysis of selected genes after 10nM siRNA-1 treatment for 72h in MDA-MB-231 and BT-20 cells in comparison with results from MCF7 shown Fig 6I. E. BAX/BCL2 ratio in BT-20 and MDA-MB-231 in comparison with MCF7 cells (data from Fig 6J), after siRNA-1 exposure (*: p 0.05, **: p 0.01).(TIF) pone.0208982.s008.tif (1000K) GUID:?C1AF5AE5-8FCC-4B2D-99F5-9C22B762F29B S4 Fig: Expression analysis of CHRNA5 expression with respect to TP53 status. A-B METABRIC (A) and TCGA(B) datasets for TP53 mutant and wild type patients.(TIF) pone.0208982.s009.tif (157K) GUID:?09AC3214-F77E-4B89-8BF5-97DF278234AB S5 Fig: Preliminary analysis of relative cell viability in CHRNA5 siRNA-1 treated cells in response to topoisomerase inhibitors Camptothecin (CPT) and Doxorubicin (DOXO). A-B. Relative cell viability of 72h exposure of CPT (0-2uM) (A) or DOXO (0-2uM) (B) and 10nM siRNA-1 treated MCF7 cells, or in combination with the corresponding siRNA-CN controls. Treatments having the same drug and DMSO concentrations were shown on the x-axis as groups; Labels: drug alone (a), drug+siRNA-CN (b), and drug+siRNA-1(c). Letters on top of the siRNA-CN (b) or siRNA-1 exposed (c) treatments are labels indicating the treatment identity (a, b, or c, as defined above) significantly different based on MAK-683 Tukey HSD corrected One-Way ANOVA results (n = 3 per group; p adj. 0.05).(TIF) pone.0208982.s010.tif (519K) GUID:?13B2F6D2-0412-4099-830E-FE275AB8B9C2 S6 Fig: Densitometry measurements. A-B. Two-Way ANOVA of densitometry measurements of cleaved CASP7/total CASP7 (A) and pH2AX (B) in DMSO, CPT, and DOXO groups.(TIF) pone.0208982.s011.tif (334K) GUID:?6EAF2DCA-BE8B-4854-B83C-050B220AE525 Data Availability StatementAll relevant data are within the paper and its Supporting Information files. Gene expression microarray data can be accessed from GEO database ( under the accession number GSE89333. Abstract Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) is an important susceptibility locus for nicotine addiction and lung cancer. Depletion of MAK-683 CHRNA5 has been associated with reduced cell viability, increased apoptosis and alterations in cellular motility in different cancers yet not in breast cancer. Herein we first showed the expression of CHRNA5 was variable and positively correlated with the fraction of total genomic alterations in breast cancer cell lines and tumors indicating its potential role in MAK-683 DNA damage response (DDR). Next, we demonstrated that silencing of CHRNA5 expression in MCF7 breast cancer cell line by RNAi affected expression of genes involved in cytoskeleton, TP53 signaling, DNA synthesis and repair, cell cycle, and apoptosis. The transcription profile of CHRNA5 depleted MCF7 cells showed a significant positive correlation with that of A549 lung cancer cell line while exhibiting a negative association with the CHRNA5 co-expression profile obtained from Cancer Cell Line Encylopedia (CCLE). Moreover, it exhibited high similarities with published MCF7 expression profiles obtained from.

Scroll to top